Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2025)

Caris Life Sciences has reported Income from Continuing Operations over the past 2 years, most recently at 81957000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 81957000.0 for Q4 2025, up 321.82% from a year ago — trailing twelve months through Dec 2025 was 2455000.0 (changed N/A YoY), and the annual figure for FY2025 was 68088000.0, up 75.85%.
  • Income from Continuing Operations for Q4 2025 was 81957000.0 at Caris Life Sciences, up from 24325000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CAI hit a ceiling of 81957000.0 in Q4 2025 and a floor of 71790000.0 in Q2 2025.